NCT07144735

Allogeneic γδT Cells in Glioblastoma

Allogeneic Gamma Delta (γδ) T Cells for the Treatment of Glioblastoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.

Conditions

• Glioblastoma (GBM)
• Glioblastoma Multiforme (GBM)

Interventions

Type	Name	Description
DRUG	Allogeneic γδ T (ABOUT) cells	Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.

Timeline

• Start date: 2025-04-01
• Primary completion: 2027-12-01
• Completion: 2030-12-01
• First posted: 2025-08-27
• Last updated: 2025-08-27

Locations

3 sites across 1 country: China